Cell surface adhesion molecules and cytokine profiles in primary progressive multiple sclerosis.

Area of Science:

• Neuroimmunology
• Neurology
• Biomarker Discovery

Background:

• Primary progressive multiple sclerosis (PPMS) is characterized by relentless neurodegeneration.
• Understanding the molecular mechanisms driving PPMS disease activity is crucial for developing targeted therapies.
• Adhesion molecules (AMs) and cytokines are implicated in inflammatory and neurodegenerative processes.

Purpose of the Study:

• To evaluate the utility of AM and cytokine/chemokine expressions in blood and CSF as markers of disease activity in PPMS.
• To compare these expressions between PPMS, secondary progressive MS (SPMS), and healthy controls.
• To correlate AM and cytokine levels with MRI-derived measures of disease burden and clinical disability.

Main Methods:

• Studied expression of AMs and 17 cytokines in blood and CSF of PPMS (n=25), SPMS (n=18), and control (n=11) groups.
• Compared AM and cytokine levels between groups.
• Correlated biomarker levels with MRI findings (lesion volume, atrophy) and Expanded Disability Status Scale (EDSS) scores.

Main Results:

• Elevated expressions of very late activation antigen 4 (VLA-4), lymphocyte function-associated antigen 1 (LFA-1), and intercellular adhesion molecule 1 (ICAM-1) in blood and CSF of PPMS patients compared to controls.
• Higher ICAM-1 levels in blood and CSF in PPMS vs. SPMS; higher VCAM-1 in PPMS blood.
• Evidence of intrathecal synthesis of interleukin-8 (IL-8) and monocyte chemoattractant protein-1 (MCP-1) in PPMS.
• CSF VLA-4 correlated with cerebral lesion volume and diffuse lesions; CSF LFA-1 correlated with spinal T2 lesions.
• Serum MIP-1beta correlated with T2 lesion load and EDSS score in PPMS.

Conclusions:

• Upregulated AMs in blood and CSF suggest their involvement in PPMS pathogenesis.
• Intrathecal synthesis of MCP-1 and IL-8 further supports the role of inflammation in PPMS.
• AMs and specific chemokines show potential as biomarkers for disease activity and progression in PPMS.